Bibliographic information

GuidelineMental Health Gap Action Programme (‎mhGAP)‎ guideline for mental, neurological and substance use disorders, [‎3rd ed.]‎.
Year of Publication2023
Issuing InstitutionWorld Health Organization

Recommendation

Updated

Fluoxetine, olanzapine, quetiapine, valproic acid (sodium valproate) or venlafaxine should be considered for adults with bipolar depression. If fluoxetine or venlafaxine are chosen, they should be co-administered with a mood stabilizer (namely quetiapine, olanzapine, carbamazepine, valproic acid [sodium valproate], lithium).

Recommended in favor

Conditional

Notes and Remarks

Remarks y Please refer to recommendation PSY8 to find further information on the recommendations for mood stabilizer and antipsychotic use in maintenance treatment.

Implementation considerations y People living with bipolar disorders should be involved in medicine choice in a supported decision-making process. y Acquisition costs can differ substantially and also throughout the world. y Lithium carbonate, sodium valproate (valproic acid), carbamazepine and quetiapine (therapeutic alternatives: aripiprazole, olanzapine, paliperidone) are available in the WHO EML (13). y Antidepressant treatment should begin at a low dose and be increased gradually if necessary. y Individuals should be monitored carefully for early signs of manic symptoms. Antidepressants should be stopped soon after remission of depressive symptoms, while mood stabilizer should be continued.